Bioengineering novel chimeric microrna-34a for prodrug cancer therapy

High-yield expression and purification, and structural and functional characterization

Wei Peng Wang, Pui Yan Ho, Qiu Xia Chen, Balasubrahmanyam Addepalli, Patrick A. Limbach, Mei Mei Li, Wen Juan Wu, Joseph L. Jilek, Jing Xin Qiu, Hong Jian Zhang, Tianhong Li, Theodore Wun, Ralph W deVere White, Kit Lam, Aiming Yu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Development of anticancer treatments based on microRNA (miRNA/miR) such as miR-34a replacement therapy is limited to the use of synthetic RNAs with artificial modifications. Herein, we present a new approach to a high-yield and large-scale biosynthesis, in Escherichia coli using transfer RNA (tRNA) scaffold, of chimeric miR-34a agent, which may act as a prodrug for anticancer therapy. The recombinant tRNA fusion pre-miR-34a (tRNA/mir-34a) was quickly purified to a high degree of homogeneity (.98%) using anion-exchange fast protein liquid chromatography, whose primary sequence and post-transcriptional modifications were directly characterized by mass spectrometric analyses. Chimeric tRNA/mir-34a showed a favorable cellular stability while it was degradable by several ribonucleases. Deep sequencing and quantitative real-time polymerase chain reaction studies revealed that tRNA-carried pre-miR-34a was precisely processed to mature miR-34a within human carcinoma cells, and the same tRNA fragments were produced from tRNA/mir-34a and the control tRNA scaffold (tRNA/MSA). Consequently, tRNA/mir-34a inhibited the proliferation of various types of human carcinoma cells in a dose-dependent manner and to a much greater degree than the control tRNA/MSA, which was mechanistically attributable to the reduction of miR-34a target genes. Furthermore, tRNA/mir-34a significantly suppressed the growth of human non-small-cell lung cancer A549 and hepatocarcinoma HepG2 xenograft tumors in mice, compared with the same dose of tRNA/MSA. In addition, recombinant tRNA/mir-34a had no or minimal effect on blood chemistry and interleukin-6 level in mouse models, suggesting that recombinant RNAs were well tolerated. These findings provoke a conversation on producing biologic miRNAs to perform miRNA actions, and point toward a new direction in developing miRNA-based therapies.

Original languageEnglish (US)
Pages (from-to)131-141
Number of pages11
JournalJournal of Pharmacology and Experimental Therapeutics
Volume354
Issue number2
DOIs
StatePublished - Aug 1 2015

Fingerprint

Bioengineering
Prodrugs
Transfer RNA
MicroRNAs
Neoplasms
Therapeutics
Antiporters
Carcinoma
High-Throughput Nucleotide Sequencing
Ribonucleases
Heterografts
Non-Small Cell Lung Carcinoma
Liquid Chromatography
Real-Time Polymerase Chain Reaction
Interleukin-6

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Bioengineering novel chimeric microrna-34a for prodrug cancer therapy : High-yield expression and purification, and structural and functional characterization. / Wang, Wei Peng; Ho, Pui Yan; Chen, Qiu Xia; Addepalli, Balasubrahmanyam; Limbach, Patrick A.; Li, Mei Mei; Wu, Wen Juan; Jilek, Joseph L.; Qiu, Jing Xin; Zhang, Hong Jian; Li, Tianhong; Wun, Theodore; deVere White, Ralph W; Lam, Kit; Yu, Aiming.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 354, No. 2, 01.08.2015, p. 131-141.

Research output: Contribution to journalArticle

Wang, Wei Peng ; Ho, Pui Yan ; Chen, Qiu Xia ; Addepalli, Balasubrahmanyam ; Limbach, Patrick A. ; Li, Mei Mei ; Wu, Wen Juan ; Jilek, Joseph L. ; Qiu, Jing Xin ; Zhang, Hong Jian ; Li, Tianhong ; Wun, Theodore ; deVere White, Ralph W ; Lam, Kit ; Yu, Aiming. / Bioengineering novel chimeric microrna-34a for prodrug cancer therapy : High-yield expression and purification, and structural and functional characterization. In: Journal of Pharmacology and Experimental Therapeutics. 2015 ; Vol. 354, No. 2. pp. 131-141.
@article{85166996bd7c406fa68fc549caae1b29,
title = "Bioengineering novel chimeric microrna-34a for prodrug cancer therapy: High-yield expression and purification, and structural and functional characterization",
abstract = "Development of anticancer treatments based on microRNA (miRNA/miR) such as miR-34a replacement therapy is limited to the use of synthetic RNAs with artificial modifications. Herein, we present a new approach to a high-yield and large-scale biosynthesis, in Escherichia coli using transfer RNA (tRNA) scaffold, of chimeric miR-34a agent, which may act as a prodrug for anticancer therapy. The recombinant tRNA fusion pre-miR-34a (tRNA/mir-34a) was quickly purified to a high degree of homogeneity (.98{\%}) using anion-exchange fast protein liquid chromatography, whose primary sequence and post-transcriptional modifications were directly characterized by mass spectrometric analyses. Chimeric tRNA/mir-34a showed a favorable cellular stability while it was degradable by several ribonucleases. Deep sequencing and quantitative real-time polymerase chain reaction studies revealed that tRNA-carried pre-miR-34a was precisely processed to mature miR-34a within human carcinoma cells, and the same tRNA fragments were produced from tRNA/mir-34a and the control tRNA scaffold (tRNA/MSA). Consequently, tRNA/mir-34a inhibited the proliferation of various types of human carcinoma cells in a dose-dependent manner and to a much greater degree than the control tRNA/MSA, which was mechanistically attributable to the reduction of miR-34a target genes. Furthermore, tRNA/mir-34a significantly suppressed the growth of human non-small-cell lung cancer A549 and hepatocarcinoma HepG2 xenograft tumors in mice, compared with the same dose of tRNA/MSA. In addition, recombinant tRNA/mir-34a had no or minimal effect on blood chemistry and interleukin-6 level in mouse models, suggesting that recombinant RNAs were well tolerated. These findings provoke a conversation on producing biologic miRNAs to perform miRNA actions, and point toward a new direction in developing miRNA-based therapies.",
author = "Wang, {Wei Peng} and Ho, {Pui Yan} and Chen, {Qiu Xia} and Balasubrahmanyam Addepalli and Limbach, {Patrick A.} and Li, {Mei Mei} and Wu, {Wen Juan} and Jilek, {Joseph L.} and Qiu, {Jing Xin} and Zhang, {Hong Jian} and Tianhong Li and Theodore Wun and {deVere White}, {Ralph W} and Kit Lam and Aiming Yu",
year = "2015",
month = "8",
day = "1",
doi = "10.1124/jpet.115.225631",
language = "English (US)",
volume = "354",
pages = "131--141",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Bioengineering novel chimeric microrna-34a for prodrug cancer therapy

T2 - High-yield expression and purification, and structural and functional characterization

AU - Wang, Wei Peng

AU - Ho, Pui Yan

AU - Chen, Qiu Xia

AU - Addepalli, Balasubrahmanyam

AU - Limbach, Patrick A.

AU - Li, Mei Mei

AU - Wu, Wen Juan

AU - Jilek, Joseph L.

AU - Qiu, Jing Xin

AU - Zhang, Hong Jian

AU - Li, Tianhong

AU - Wun, Theodore

AU - deVere White, Ralph W

AU - Lam, Kit

AU - Yu, Aiming

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Development of anticancer treatments based on microRNA (miRNA/miR) such as miR-34a replacement therapy is limited to the use of synthetic RNAs with artificial modifications. Herein, we present a new approach to a high-yield and large-scale biosynthesis, in Escherichia coli using transfer RNA (tRNA) scaffold, of chimeric miR-34a agent, which may act as a prodrug for anticancer therapy. The recombinant tRNA fusion pre-miR-34a (tRNA/mir-34a) was quickly purified to a high degree of homogeneity (.98%) using anion-exchange fast protein liquid chromatography, whose primary sequence and post-transcriptional modifications were directly characterized by mass spectrometric analyses. Chimeric tRNA/mir-34a showed a favorable cellular stability while it was degradable by several ribonucleases. Deep sequencing and quantitative real-time polymerase chain reaction studies revealed that tRNA-carried pre-miR-34a was precisely processed to mature miR-34a within human carcinoma cells, and the same tRNA fragments were produced from tRNA/mir-34a and the control tRNA scaffold (tRNA/MSA). Consequently, tRNA/mir-34a inhibited the proliferation of various types of human carcinoma cells in a dose-dependent manner and to a much greater degree than the control tRNA/MSA, which was mechanistically attributable to the reduction of miR-34a target genes. Furthermore, tRNA/mir-34a significantly suppressed the growth of human non-small-cell lung cancer A549 and hepatocarcinoma HepG2 xenograft tumors in mice, compared with the same dose of tRNA/MSA. In addition, recombinant tRNA/mir-34a had no or minimal effect on blood chemistry and interleukin-6 level in mouse models, suggesting that recombinant RNAs were well tolerated. These findings provoke a conversation on producing biologic miRNAs to perform miRNA actions, and point toward a new direction in developing miRNA-based therapies.

AB - Development of anticancer treatments based on microRNA (miRNA/miR) such as miR-34a replacement therapy is limited to the use of synthetic RNAs with artificial modifications. Herein, we present a new approach to a high-yield and large-scale biosynthesis, in Escherichia coli using transfer RNA (tRNA) scaffold, of chimeric miR-34a agent, which may act as a prodrug for anticancer therapy. The recombinant tRNA fusion pre-miR-34a (tRNA/mir-34a) was quickly purified to a high degree of homogeneity (.98%) using anion-exchange fast protein liquid chromatography, whose primary sequence and post-transcriptional modifications were directly characterized by mass spectrometric analyses. Chimeric tRNA/mir-34a showed a favorable cellular stability while it was degradable by several ribonucleases. Deep sequencing and quantitative real-time polymerase chain reaction studies revealed that tRNA-carried pre-miR-34a was precisely processed to mature miR-34a within human carcinoma cells, and the same tRNA fragments were produced from tRNA/mir-34a and the control tRNA scaffold (tRNA/MSA). Consequently, tRNA/mir-34a inhibited the proliferation of various types of human carcinoma cells in a dose-dependent manner and to a much greater degree than the control tRNA/MSA, which was mechanistically attributable to the reduction of miR-34a target genes. Furthermore, tRNA/mir-34a significantly suppressed the growth of human non-small-cell lung cancer A549 and hepatocarcinoma HepG2 xenograft tumors in mice, compared with the same dose of tRNA/MSA. In addition, recombinant tRNA/mir-34a had no or minimal effect on blood chemistry and interleukin-6 level in mouse models, suggesting that recombinant RNAs were well tolerated. These findings provoke a conversation on producing biologic miRNAs to perform miRNA actions, and point toward a new direction in developing miRNA-based therapies.

UR - http://www.scopus.com/inward/record.url?scp=84941555844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941555844&partnerID=8YFLogxK

U2 - 10.1124/jpet.115.225631

DO - 10.1124/jpet.115.225631

M3 - Article

VL - 354

SP - 131

EP - 141

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -